FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549	
-------------	------	-------	--

STATEMENT	OF CH	ANGES	IN	BENE	FICIA	١L

OMB APPI	ROVAL						
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

**OWNERSHIP** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Smith Cynthia					2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS, INC. [ AGIO ]									(Ch	eck all appli X Directo	cable) or	ig Pers	son(s) to Iss	vner	
(Last) (First) (Middle) C/O AGIOS PHARMACEUTICALS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 08/11/2023										below)	(give title	e Other (s below)		specify
88 SIDNEY STREET				4. I									Line	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person						
(Street)	IDGE M	1A	02139														iled by Mo		n One Repor	
(City)	(5	State)	(Zip)		Ru	Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to														
												ction was r					on or writter	n plan t	hat is intende	d to
		Tab	le I - Nor	า-Deriv	ative	Sec	curiti	ies Ac	cqu	ired, I	Disp	osed o	of, or	Ben	eficial	ly Owne	d			
Date					Exe		2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		4. Securities Acquir Disposed Of (D) (Ins 5)				Benefici	es ally Following	Form (D) o	n: Direct or Indirect ostr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
										Code	v	Amount		(A) or (D)	Price	Transac	ansaction(s) nstr. 3 and 4)			(IIISti. 4)
Common stock				08/1	1/2023					M		2,30	2 A \$0		2,302			D		
		Т	able II -									sed of onverti				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,		Transaction Code (Instr.		n of		Date Exe piration onth/Day	Date		7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securitie Beneficia Owned Following Reported Transacti (Instr. 4)	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Dat Exe	te ercisabl		xpiration ate	Title	1	Amount or Number of Shares					
Restricted stock units	(1)	08/11/2023			M			2,302		(2)		(2)	Comi		2,302	\$0	4,604		D	

## **Explanation of Responses:**

- 1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- 2. The restricted stock units were granted on August 11, 2022. Beginning on August 11, 2023, the shares underlying the restricted stock units will vest in three equal annual installments.

## Remarks:

/s/ William Cook, as attorneyin-fact for Cynthia Smith

08/15/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.